Brompheniramine maleate


Questions | Reviews ***~

We don't currently have any questions about Brompheniramine maleate.

Brompheniramine maleate
Brompheniramine maleate (Dimetane)
Brompheniramine maleate
(brohm-fen- EAR-ah-meen)
Pregnancy Category: B Brombay Chlorphed Conjec-B Cophene-B Diamine T.D. Dimetane Extentabs Dimetane-Ten Histaject Modified Nasahist B ND Stat Revised Oraminic II Sinusol-B Veltane (Rx; Dimetane and Dimetane Extentabs are OTC)

Classification: Antihistamine, alkylamine type

See Also: See also Antihistamines .

Action/Kinetics: Fewer sedative effects. t 1/2: 25 hr. Time to peak effect: 3-9 hr. Duration: 4-25 hr.

Uses: Allergic rhinitis (oral). Parenterally to treat allergic reactions to blood or plasma; adjunct to treat anaphylaxis; uncomplicated allergic conditions when PO therapy is not possible or is contraindicated.

Contraindications: Use in neonates.

Special Concerns: Geriatric clients may be more sensitive to the usual adult dose.

How Supplied: Capsule: 4 mg; Elixir: 2 mg/5 mL; Injection: 10 mg/mL; Tablet: 4 mg; Tablet, Extended Release: 12 mg

Dosage
?Liqui-Gels Allergic rhinitis.
Adults and children over 12 years: 4 mg q 4-6 hr, not to exceed 24 mg/day. ?IM, IV, SC
Adults: usual, 10 mg (range: 5-20 mg) b.i.d. (maximum daily dose: 40 mg); pediatric, under 12 years: 0.5 mg/kg/day (15 mg/m 2 /day) divided into three or four doses.

Brompheniramine maleate Ratings

Overall Rating:

3.5***~

 

(based on 3 reviews)

Effectiveness:

***

Ease of Use:

****~

Overall Satisfaction:

**~

Reviewit

Reviews

Brompheniramine maleate
3.5

Effectiveness: ****

Ease of Use: ****

Overall Satisfaction: **

Avatar_thumbnail

Sachin, Sachin - 01/11/2014

that arterolane mataele is not a NCE. I've only said that Synriam is not a NCE and Ranbaxy's press release seems to be quite clear that Synriam is a FDC and the impression given by the press release is that the invention lies in creation of the FDC. No where does Ranbaxy claim that their invention lies in the development of a NCE, although I'm not denying that this could be the case. Also, I never 'cast aside' or belittled Ranbaxy's achievement. In fact I used the word 'commendable' - I was only critical of some of the media reports which seem to indicate that this was the first time that an Indian company invented a FDC. As for the rhetoric over it being an Indian drug, I think we need to collect more information before jumping to any conclusions. From the information that I have been able to gather, Ranbaxy is pretty much a Japanese company, the drug in question is reportedly being manufactured by Ranbaxy in its Chinese plants and the drug itself was discovered initially by a Swiss non-profit - MMV, with a team consisting largely of foreign scientists. If I have tracked the right patent for the drug in question then in that case it is quite clear that only 2 of the 9 inventors of this drug are Indians, while one is of Indian origin. I could be wrong on this patent and I'm waiting for confirmation on the patent covering the drug. From what I gather Ranbaxy took over only at the stage of clinical trials. And yes, they deserve credit for taking the risk of investing and conducting large scale clinical trials but even for the clinical trials they received funding from the govt. So there really wasn't much risk. Which ever way you look at it Ranbaxy does deserve credit for cracking this new public private mode of development. Regards,Prashant